Healthcare - Press Releases

YUTIQ addresses a significant unmet need in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The uveitis treatment market is projected to grow steadily, driven by rising incidence and improved diagnosis, positioning YUTIQ for strong market adoption.

SAN DIEGO, May 6, 2025 /PRNewswire/ --Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the "Class Period"), have until July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutical class action lawsuit charges West Pharmaceutical and certain of West Pharmaceutical's current and former top executives with violations of the Securities Exchange Act of 1934.

Rsum de l'actualit

LEXINGTON, Mass., May 6, 2025 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy to purchase 200,000 shares of Curis common stock, with a grant date of May 1, 2025 (the "Inducement Grant").

TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery. Clobetasol propionate ophthalmic suspension, 0.05% (APP13007) was approved by the U.S. Food and Drug Administration (FDA) in 2024. APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT nanoparticle formulation platform. The novel formulation enables a convenient and straightforward dosing regimen, while providing rapid and sustained relief of inflammation and pain, which in Phase 3 trials proved statistically and clinically superior to its matching placebo (p<0.001).

WASHINGTON, May 6, 2025 /PRNewswire/ -- The Independence Fund, a national non-profit organization dedicated to serving the needs of catastrophically wounded Veterans and their families, was honored to join six of our nation's Veterans at today's Senate Committee on Veterans' Affairs hearing, "Veterans at the Forefront: Secretary Collins on the Future at VA."

SAN DIEGO, May 6, 2025 /PRNewswire/ -- Adcentrx Therapeutics("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program, ADRX-0706, for the treatment of patients with locally advanced or metastatic squamous cell cervical cancer.

CHICAGO, May 6, 2025 /PRNewswire/ -- Veltex Corporation (OTCQB: VLXC), a premier Health and Wellness Acquisition Firm, is pleased to announce key enhancements to its leadership structure as part of its continued growth strategy and mission to serve communities impacted by substance use disorder.

LOS ANGELES, May 6, 2025 /PRNewswire/ -- Dr. Austin Harris, Dr. Austin Harris, MD, founder of NeuroRelief Ketamine & Infusion Therapy, offers a $1,000 grant to support student athletes balancing academics and sports. This scholarship is open to undergraduates at accredited U.S. colleges who show dedication both on the field and in the classroom.

CHICO, Calif., May 6, 2025 /PRNewswire/ -- Dr. ZacharyLipman, a dedicated physician and advocate for well-being, is pleased to announce the establishment of the Dr. Zachary Lipman Scholarship for Student Athletes. This one-time award of $1,000 aims to provide financial assistance to undergraduate students who actively participate in athletics and demonstrate a clear intention to pursue a career within the sports field.

SUZHOU, China, May 6, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC), key assets in CStone Pipeline 2.0, have been delivered at the 2025 American Association for Cancer Research (AACR) Annual Meeting.

LOS ANGELES, May 6, 2025 /PRNewswire/ --May isALS Awareness Month, and the ALS Network is committed to raising awareness and understanding of the devastating disease that has no known cure. This month, we highlight the power of community and invite everyone to explore the many ways to get involved, give back, and learn more.

TOKYO, May 7, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint research* with RIBOMIC Inc. (President: Yoshikazu Nakamura, Headquarters: Minato-ku, Tokyo, hereinafter referred to as "RIBOMIC"), a drug discovery startup focused on the development and production of aptamer pharmaceuticals, on the development of technology for controlling the pharmacokinetics of nucleic acid aptamers using the antibody-drug conjugate (ADC) manufacturing technology "AJICAP" (hereinafter referred to as "AJICAP"). As a result of this research, RIBOMIC has successfully extended the half-life of a conjugate of nucleic acid aptamers and the Fc region of immunoglobulins in the bloodstream.

TOKYO, May 6, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint research* with RIBOMIC Inc. (President: Yoshikazu Nakamura, Headquarters: Minato-ku, Tokyo, hereinafter referred to as "RIBOMIC"), a drug discovery startup focused on the development and production of aptamer pharmaceuticals, on the development of technology for controlling the pharmacokinetics of nucleic acid aptamers using the antibody-drug conjugate (ADC) manufacturing technology "AJICAP" (hereinafter referred to as "AJICAP"). As a result of this research, RIBOMIC has successfully extended the half-life of a conjugate of nucleic acid aptamers and the Fc region of immunoglobulins in the bloodstream.

BUDAPEST, Hongrie, 7 mai 2025 /PRNewswire/ -- Un centre offrant un soutien mdical et ducatif ainsi qu'un abri aux femmes vulnrables a t construit Bamako, la capitale du Mali, grce l'aide financire de Gedeon Richter. En tant que l'un des principaux fabricants mondiaux de mdicaments pour la sant des femmes, Richter souligne l'importance de promouvoir la sant et la qualit de vie des femmes dans tous les pays o il opre. Avec ce nouveau centre, en mesure d'accueillir des dizaines de femmes dfavorises de la rgion, Richter a pour objectif de venir en aide prs de 300 femmes par an. Cette initiative n'est pas un simple investissement ponctuel, car l'entreprise pharmaceutique s'est engage soutenir long terme le fonctionnement de la Maison de l'Espoir.

BUDAPEST, Hungra, 7 de mayo de 2025 /PRNewswire/ -- En Bamako, capital de Mali, se ha construido un centro que ofrece atencin mdica, apoyo educativo y albergue para mujeres vulnerables, con la ayuda financiera de Gedeon Richter. Como uno de los principales fabricantes mundiales de medicamentos para la salud femenina, Richter enfatiza la importancia de promover la salud y la calidad de vida de las mujeres en todos los pases donde opera. Con el nuevo centro, capaz de albergar a decenas de mujeres desfavorecidas de la regin, Richter aspira a brindar ayuda a casi 300 mujeres al ao. Esta iniciativa no es una inversin puntual, ya que la compaa farmacutica se compromete a apoyar a largo plazo el funcionamiento del centro House of Hope.

SAN FRANCISCO, May 6, 2025 /PRNewswire/ -- Caplight Technologies, an innovator in private market data and trading infrastructure, today announced the issuance of a patent by the United States Patent and Trademark Office protecting Caplight's proprietary method for estimating private company stock prices using secondary market transaction data.

Labbit's graph-based architecture supports the unique needs of Grant's different lab environments while unifying data to deliver full traceability for quality assurance and regulatory compliance.

More than half of Aging Life Care Managers' clients are living with dementia, a new national survey finds.

Seven months after the FDA approved the reintroduction of Roche's eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary cause of blindness related to diabetes. This marks the second approved indication for Susvimo, which was initially cleared in October 2021 as an alternative to frequent eye injections for wet age-related macular degeneration.

PLAINSBORO, N.J., April 30, 2025 /PRNewswire/ -- Today, The New England Journal of Medicine(NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which investigated the effects of once-weekly subcutaneous semaglutide 2.4 mg on liver histology compared to placebo at 72 weeks in adults with MASH and moderate to advanced liver fibrosis (stage 2 or 3). At Week 72, the first primary endpoint showed 62.9% of people treated with semaglutide 2.4 mg achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.3% on placebo with estimated difference in responder proportions (EDP) of 28.7% (95% CI, 21.1 to 36.2; P<0.001). For the second primary endpoint at Week 72, 36.8% of people treated with semaglutide 2.4 mg achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.4% on placebo (EDP, 14.4%; 95% CI, 7.5 to 21.3; P<0.001).1

CALGARY, AB, April 30, 2025 /PRNewswire/ -Willow Biosciences Inc. (the "Company") (TSX:WLLW) (OTCQB: CANSF) announces the completion today of the sale (the "Transaction") of its wholly-owned operating subsidiary, Epimeron USA, Inc., to the U.S. subsidiary of Mycofeast Ltd., a privately-held, arms-length entity based in the United Kingdom (the "Purchaser"), pursuant to the terms of a share purchase agreement dated March 14, 2025 (the "Share Purchase Agreement"), between the Company and the Purchaser.

FREDERICK, Md., April 30, 2025 /PRNewswire/ -- RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science. This collaboration aims to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionize the treatment of degenerative disease.

YMCA Launches Interactive Teen Mental Health Resource Hub for Mental Health Awareness Month

PALMETTO, Fla., April 30, 2025 /PRNewswire/ -- BayCare, the leading health care system in West Central Florida, broke ground today on BayCare Hospital Manatee, its 17th hospital, and BayCare HealthHub(Manatee). This milestone marks a significant step in expanding access to health care for the growing Manatee County community. The hospital will be the county's first not-for-profit hospital and the only hospital north of the Manatee River.